Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.38 |
| ▸ | PPARA | Q07869 | 11/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.30 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.30 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28694764 | 1.00 | PPARG (0.38) | PPARGPPARACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL28694767 | 1.00 | PPARG (0.38) | PPARGPPARACYP2D6SLC6A2SLC6A4 | |
| SCHEMBL29367873 | 0.95 | PPARG (0.38) | PPARGPPARAPTGDR2AKR1C3AKR1C2 | |
| SCHEMBL22823973 | 0.95 | PPARG (0.38) | PPARGPPARAPTGDR2AKR1C3AKR1C2 | |
| SCHEMBL28676544 | 0.95 | PPARG (0.38) | PPARGPPARAPTGDR2AKR1C3AKR1C2 | |
| SCHEMBL28697512 | 0.90 | PPARG (0.37) | PPARGPPARAPTGDR2PPARD | |
| SCHEMBL28697514 | 0.90 | PPARG (0.37) | PPARGPPARAPTGDR2PPARD | |
| SCHEMBL22823983 | 0.86 | PPARG (0.38) | PPARGPPARAPTGDR2AKR1C3AKR1C2 | |
| SCHEMBL29365366 | 0.86 | PPARG (0.38) | PPARGPPARAPTGDR2AKR1C3AKR1C2 | |
| SCHEMBL28687049 | 0.86 | PPARG (0.38) | PPARGPPARAPTGDR2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| CN-114008012-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2025-02-25 | — | — | CN | claimed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | claimed |
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2022-12-08 | — | — | US | claimed |
| EP-3986852-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | claimed |
| CN-114008012-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2022-02-01 | — | — | CN | claimed |
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | disclosed |
| CN-114008012-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | disclosed |
| EP-3986852-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| CN-114008012-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388938-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CACNB1, SMN1; SMN2 | PPARG 3395/4885PPARA 3710/4885CYP2D6 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.